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Glycolysis is essential to Trypanosoma brucei, the causative agent of African sleeping sickness, suggesting
enzymes in the pathway could be targets for drug development. Ebselen (2-phenyl-1,2-benzisoselenazol-
3(2H)-one, EbSe) was identiﬁed in a screen as a potent inhibitor of T. brucei hexokinase 1 (TbHK1), the
ﬁrst enzyme in the pathway. EbSe has a history of promiscuity as an enzyme inhibitor, inactivating pro-
teins through seleno-sulﬁde conjugation with Cys residues. Indeed, dilution of TbHK1 and inhibitor fol-
lowing incubation did not temper inhibition suggesting conjugate formation. Using mass spectrometry to
analyze EbSe-based modiﬁcations revealed that two Cys residues (C327 and C369) were oxidized after
treatment. Site-directed mutagenesis of C327 led to enzyme inactivation indicating that C327 was essen-
tial for catalysis. C369 was not essential, suggesting that EbSe inhibition of TbHK1 was the consequence
of modiﬁcation of C327 via thiol oxidation. Additionally, neither EbSe treatment nor mutation of the nine
TbHK1 Cys residues appreciably altered enzyme quaternary structure.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Trypanosoma brucei is the causative agent of African sleeping
sickness in humans and nagana in livestock, both of which have
tremendous impact on the lives of people in sub-Saharan Africa
(Brun et al., 2010). Bloodstream form (BSF) T. brucei, the lifecycle
stage that grows rapidly in the blood of the mammalian host, de-
pends solely on glycolysis for ATP production. As a consequence,glycolytic enzymes from the parasite have been considered as po-
tential targets for therapeutic design.
The ﬁrst enzyme activity in glycolysis, which transfers a phos-
phoryl group from ATP to glucose, is catalyzed by hexokinases
(HK). T. brucei harbors two hexokinase genes, TbHK1 and TbHK2,
and both gene products are essential to BSF parasite (Chambers
et al., 2008a). The TbHKs, whether puriﬁed from parasites or heter-
ologously expressed in Escherichia coli, oligomerize into hexamers
(MIsset et al., 1986; Chambers et al., 2008b). Due to the 98% iden-
tity of TbHK1 and TbHK2, the contribution of both to hexamer for-
mation in vivo has remained elusive. Nonetheless, recombinant
heterohexamers generated in vitro with known ratios of TbHK1
and TbHK2 have kinetic properties more similar to those reported
for T. brucei-derived TbHK than recombinant TbHK homohexamers
(Chambers et al., 2008b), suggesting that in the parasite oligomers
are most likely heterohexamers. Notably, the composition of the
heterohexamers in vivo is regulated in response to the nutritional
environment in which the cells are cultured. The mechanisms be-
hind this dynamic hexamerization, including the enzyme protein
domains that participate in oligomerization, remain to be
elucidated.
TbHK1 has previously been genetically and chemically
validated as a potential target for therapeutic design. Further, the
enzyme has been the subject of both structure-based approaches
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pounds with potential as leads in therapeutic development. The
HTS campaign included the screening of 220,233 compounds for
inhibitors of TbHK1 (Sharlow et al., 2010a,b). From this effort ten
inhibitors, including six structurally related isobenzothiazolinone
inhibitors have been identiﬁed. Ebselen (2-phenyl-1,2-ben-
zisoselenazol-3(2H)-one, EbSe, Fig. 1A), a selenium containing var-
iant of isobenzothiazolinones, was the most potent TbHK1
inhibitor found in the HTS campaign, with an IC50 = 0.05 ± 0.03 lM.
Notably, 2-phenyl-1,2-benzisothiazol-3(2H)-one (SID 17387000,
EbS, Fig. 1A), which differs from EbSe by replacement of the sele-
nium atom with sulfur, was also identiﬁed in the HTS as a potent
TbHK1 inhibitor (IC50 = 2.0 ± 0.5 lM).A
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Fig. 1. EbSe, a known Cys-reactive compound, inhibits TbHK1 activity. (A)
Structures of ebselen (EbSe) and ebsulfur (EbS), SID 17387000. (B) EbS and EbSe
inhibition are irreversible by dilution. TbHK1 (32 ng) was incubated with EbSe or
EbS in the assay for 15 min. Alternatively, inhibitor was incubated with enzyme
prior to addition of other assay components, which yielded a 200-fold dilution of
enzyme and inhibitor. (C) DTT can block but not reverse TbHK1 inhibition by EbSe.
TbHK1 (32 ng) was incubated with EbS or EbSe (hatched bars) followed by the
addition of DTT (100 mM) prior to assay. Experiments were performed in triplicate
and standard deviation is indicated.EbSe is known to form seleno-sulﬁde adducts with target pro-
tein Cys residues. For example, EbSe inhibited human indoleamine
2,3-dioxygenase (IDO) through covalent modiﬁcation of multiple
IDO Cys residues, causing a change in enzyme conformation and
inactivation (Terentis et al., 2010). This EbSe-based oxidization of
critical Cys residues can also result in the generation of inappropri-
ate disulﬁde linkages (Sakurai et al., 2006). Here we explore the
role Cys residues have in EbSe-based TbHK1 inhibition. Through
these efforts, we have found that EbSe oxidizes a single critical
Cys residue, rather than promiscuously modifying Cys residues.
Additionally, we have characterized the role of TbHK1 Cys residues
in enzyme activity and the impact of their modiﬁcation on oligo-
merization, ﬁnding that several of the Cys residues are essential
for catalysis and can inﬂuence hexamerization.2. Materials and methods
2.1. Reagents
Tris (2-carboxyethyl)phosphine (TCEP), glucose-6-phosphate
dehydrogenase, b-nicotinamide adenine dinucleotide (NAD+),
adenosine triphosphate (ATP), and glucose were purchased from
Sigma (St. Louis, MO). Dimethyl sulfoxide (DMSO) was purchased
from Fisher Scientiﬁc (Pittsburgh, PA), while phosphoenol pyruvate
(PEP), 2-phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen, EbSe,
PubChem SID 856002) and glucosamine were obtained from VWR
International (West Chester, PA). 3-(N-maleimidopropionyl)-biocytin
was purchased from Cayman Chemical (Ann Arbor, MI).2.2. Recombinant enzyme puriﬁcation and assay conditions
Recombinant TbHK1 was puriﬁed as described from a culture of
E. coli M15(pREP) harboring pQE30 (Qiagen, Valencia, CA) with
TbHK1 cloned in frame of a 6-His tagging sequence (Morris et al.,
2006). Brieﬂy, a 10 mL bacterial culture was used to inoculate a
1 L culture which was grown to an OD of 1 and then induced for
24 h at room temperature with 250 lM isopropyl b-D-1-thiogalac-
topyranoside (IPTG) and puriﬁed as described (Morris et al., 2006).
TbHK1 Cys variants were generated using the parental pQE30
TbHK1 construct and a QuikChange II Site-Directed Mutagenesis
Kit (Stratagene, LaJolla, CA). Primers used for the mutagenesis are
listed in Supplementary Table S1 and generation of all variants
was conﬁrmed by sequencing. Please note that despite repeated ef-
forts, C103A was not successfully generated. Protein expression
and puriﬁcation were performed as described above, with fractions
from the puriﬁcation probed by western blotting using an anti-
RGS-His6 antibody (Qiagen, Valencia, CA) to identify those harbor-
ing the recombinant protein. All variants were at least 90% pure
based on coomassie blue staining of proteins resolved by SDS–
PAGE.
HK assays were performed in triplicate as described using a
coupled reaction to measure enzyme activity (Misset and Opperdoes,
1984; Morris et al., 2006). In short, the coupled assay uses glucose-6-
phosphate dehydrogenase (G6PDH) to convert glucose-6-phosphate
(G6-P) generated by HK to 6-phosphogluconate with coincident
reduction of NADP to NADPH, which is monitored spectrophotomet-
rically at 340 nm. Note that EbSe was found to be ineffective in a
counterscreen for inhibition of G6PDH. Kinetic analyses were
performed using KaleidaGraph 4.1 (Synergy Software, Reading, PA).2.3. Mass spectrometry analysis of EbSe-treated TbHK1
Mass spectrometry was performed to map EbSe modiﬁcation on
TbHK1. First, solution samples were C4 zip tipped (Millipore)
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dried down and re-suspended in 100 ng of trypsin (Sigma, proteo-
mics grade) and digested overnight at 37 C. The digested sample
was then placed in an auto sampler vial for LC–MS/MS analysis.
Enzymatically digested samples were analyzed via liquid chro-
matography (LC)–electrospray ionization (ESI)–tandem mass spec-
trometry (MS/MS) on an Orbitrap Elite mass spectrometer
(Thermo) coupled to a Dionex 3000 nano LC system. A 20 cm 75
micron C-18 reversed phase LC column (packed in house, with
Waters ODS C18) was utilized with a 200 nL/min ﬂow rate and a
120 min gradient from 2% acetonitrile, 0.2% formic acid to 50%
acetonitrile, 0.2% formic acid. MS data were acquired in a data-
dependent strategy selecting the fragmentation events based on
the precursor abundance in the survey scan (400–1700 Th). The
resolution of the survey scan was 60,000 at m/z 400 Th with a
target value of 1e6 ions and 1 microscan. Low resolution CID
MS/MS spectra were acquired on the top 20 ions, with a target
value of 1000 ions in normal CID scan mode. MS/MS acquisition
in the linear ion trap was partially carried out in parallel to the
survey scan in the Orbitrap analyzer by using the preview mode
(ﬁrst 192 ms of the MS transient). The maximum injection time
for MS/MS was 100 ms. Dynamic exclusion was 120 s and early
expiration was enabled. The isolation window for MS/MS fragmen-
tation was set to 2 Th.
MS/MS data was searched against a custom database containing
the users provided sequence using the searching algorithm node
Sequest HT in Proteome Discoverer 1.4 (Thermo). Variable modiﬁ-
cations of oxidation on methionine and Cys, di-oxidation and tri-
oxidation of Cys, the addition of EbSe to cysteine, the substitution
of S with Se, and the conversion of Cys to dehydro-Ala were all
considered.
2.4. Native gel analysis and negative stain transmission electron
microscopy
For native gels, protein samples were diluted in native gel load-
ing buffer (10% (v/v) glycerol, 2.7 mM Tris–HCL, pH 6.8, 0.1% brom-
phenol blue) and resolved on a 4% polyacrylamide gel (4% bis
acrylamide, 375 mM Tris–Cl, pH 8.8, 0.05% (v/v) TEMED, and
0.05% ammonium persulfate) using a Tris/glycine buffer (2.7 mM
Tris–HCl and 192 mM glycine, pH 6.9) (Chambers et al., 2008b).
Proteins were detected by silver staining.
For electron microscopy, samples were prepared by placing a
drop of protein in solution on a formvar coated copper TEM grid
held in anti-capillary forceps. The protein was allowed to settle
to the grid surface for 60 s and excess liquid wicked away with a
ﬁlter paper. The grids were then stained with a drop of aqueous
2% uranyl acetate for 30 s after which the excess stain was wicked
away. Images of the negatively stained protein particles were col-
lected using a JEOL JEM 1200 EX transmission electron microscopy
equipped with a Gatan Orius 830 camera. The images were pre-
pared for publication using Adobe Photoshop.
2.5. 3-(N-Maleimidopropionyl)-biocytin (MPB) assays
TbHK1 and variants (equal amounts as determined by coomas-
sie staining of an SDS–PAGE gel) were incubated (30 min, RT) with
MPB (50 lM) in buffer (20 mM Na2HPO4, 5 mM glucose, 0.4 M
(NH4)SO4), resolved by 4% native gel electrophoresis, and mono-
mers analyzed following transfer to nitrocellulose by western blot-
ting using an anti-biotin antibody (1:10,000; Cell Signaling
Technology Danvers, MA). Relative darkness was quantitated using
ImageJ software. To score the consequences of inhibitor on MPB
labeling, TbHK1 was incubated with increasing concentrations of
inhibitor (15 min, RT) followed by addition of MPB (50 lM), and
the mixture incubated for an additional 30 min at RT.3. Results
In two independent screens for TbHK1 inhibitors, we identiﬁed
EbSe (2-phenyl-1,2-benzisoselenazol-3(2H)-one) as a potent
TbHK1 inhibitor. In the ﬁrst, a LOPAC screen, EbSe inhibited TbHK1
88.1 ± 0.6% at 10 lM. Also, EbSe and ﬁve other structurally related
isobenzothiazolinones were identiﬁed as TbHK1 inhibitors during
a high throughput screen (HTS) of 220,233 small molecules
(Sharlow et al., 2010b). While EbSe was the most potent inhibitor
identiﬁed (IC50 = 0.05 ± 0.03 lM), the ﬁnding that it can form cova-
lent seleno-suliﬁde conjugates with Cys residues or act as a Cys
oxidant suggested that it was not an ideal lead for further develop-
ment. Supporting this supposition, EbSe had been identiﬁed as an
inhibitor of a number of different enzymes in multiple validated
HTS campaigns, possibly because of its Cys-reactive nature
(Sharlow et al., 2010b).
Other Cys reactive TbHK1 inhibitors have also been identiﬁed.
For example, the thiol-reactive reagent 4-chloromercuribenzoic
acid was identiﬁed in the LOPAC screen as a potent inhibitor of
TbHK1 (84.7 ± 0.4% inhibition at 10 lM) (Sharlow et al., 2010b).
Additionally, the irreversible disulﬁde-reactive reagent tris (2-car-
boxyethyl)phosphine (TCEP) inhibited TbHK1 (IC50 = 6.6 ± 0.4 lM),
supporting the possibility that a Cys residue (or multiple Cys resi-
dues) is important for catalysis.3.1. Neither dilution, DTT, nor excess Mg2+ can reverse EbSe inhibition
of TbHK1
Six isobenzothiazolinones were identiﬁed in the HTS as potent
inhibitors of TbHK1, including EbS (SID 17387000), which is a
structural analog of EbSe that harbors a S atom in place of the Se
found in EbSe (Fig. 1). Inhibition by this compound or by EbSe
was not reversible by 200-fold dilution of the inhibitor after pre-
incubation with enzyme, suggesting a covalent modiﬁcation of
TbHK1 (Fig. 1B). Because EbSe inhibition of human IDO had been
reported to be reversible by inclusion of the reducing reagent dithi-
othreitol (DTT) (Terentis et al., 2010), we assessed the conse-
quences of this reagent on both EbS and EbSe inhibition (Fig. 1C).
Alone, DTT (100 mM) had little impact on enzyme activity. Addi-
tion of DTT after either EbS or EbSe incubation only modestly res-
cued enzyme activity. While pre-incubation of TbHK1 with DTT
prevented EbSe inhibition (data not shown), it is likely this oc-
curred as a result of DTT interacting directly with EbSe to block
association of the small molecule with the enzyme. A report
describing the formation of DTT/EbSe adducts supports this possi-
bility (Borges et al., 2005). Last, EbSe could be inhibitory to TbHK1
as a result of causing inappropriate coordination of the essential
Mg2+ cofactor. Addition of excess Mg2+ did not relieve EbSe inhibi-
tion, even at 15-fold higher concentrations than are used in the
standard reaction (data not shown).3.2. MPB as a probe for exposed Cys interactions with inhibitors
To further explore the role of surface-exposed Cys residues in
inhibitor binding, the Cys modifying reagent 3-(N-maleimidopro-
pionyl)-biocytin (MPB) was used to modify surface-exposed Cys
residues (Bayer et al., 1985). At concentrations up to 50 lM, MPB
did not impact enzyme activity; however, pre-incubation with
MPB did not appreciably alter EbSe inhibition, suggesting that
the residues accessible to MPB were not involved in the enzyme
inhibition or that EbSe could compete with the MPB modiﬁcation
or interact with free MPB.
Fig. 2. Two Cys residues on the large lobe of TbHK1 are modiﬁed in EbSe treated
samples. The predicted distribution of TbHK1 Cys residues, based on modeling to
the yeast structure, with the nine Cys residues and the catalytic base (D214)
included to indicate the active site (Chambers et al., 2008c). The  indicates the Cys
found by ESI–MS/MS to be oxidized in both untreated and EbSe-treated TbHK1,
while the  indicates the two oxidized Cys residues observed only in peptides from
treated samples.
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Because the MPB experiments did not clarify the role of Cys res-
idues in EbSe inhibition, we pursued scoring the direct conse-
quences of EbSe treatment by ESI–MS/MS. This was performed
keeping in mind that Cys residues have been described in the liter-
ature as the target of EbSe modiﬁcation, either by formation of a
selano-Cys bond between the enzyme and inhibitor or with the
EbSe serving as a thiol oxidant.
Modiﬁcations of TbHK1 were scored using digested peptides
from EbSe treated and untreated enzyme that were subjected to
ESI–MS/MS (Supplemental Data set 1). Using this approach, species
were identiﬁed with dioxidized (sulfone) and trioxidized (sulfonic
acid) modiﬁed C103 in both untreated and treated samples. In con-
trast, dioxidized and trioxidized C327 and C369 modiﬁcations
were identiﬁed only in the EbSe treated samples (Fig. 2). Peptides
bearing oxidized C327 and C369 were not observed in the un-
treated samples, suggesting that they were either not present in
the untreated sample or that the modiﬁed peptides were present
but simply not detected in the untreated samples. Lastly, EbSe-
conjugated through a seleno-sulﬁde bond to TbHK1 was not de-
tected in the treated samples.Table 1
Speciﬁc activity and sensitivity to of TbHK1 Cys variants.a
Variant Speciﬁc activity (mmol min1 lg1)
WT 0.60 ± 0.03
C103A NAb
C103S 0.17 ± 0.00
C212A NDd
C212S 0.23 ± 0.01
C242A 1.1 ± 0.12
C327A ND
C327S ND
C369A 0.24 ± 0.02
C386A ND
C386S ND
C401A 0.17 ± 0.03
C402A 0.23 ± 0.01
C445A 0.79 ± 0.01
a Experiments were performed in triplicate and standard deviation is indicated.
b NA, protein not expressed.
c Inhibition was 100% using EbSe at a concentration that inhibited WT protein 50%.
d Not determined, as activity was not detected.3.4. Mutagenesis of individual Cys residues in TbHK1
The observation that EbSe modiﬁed both C327 and C369 sug-
gested that one or both were important for catalysis and/or EbSe
inhibition. Further, it hinted at the possibility of generating EbSe-
insensitive enzyme by alteration of the putative target residues.
To explore the role of the nine TbHK1 Cys residues (Fig. 2) in catal-
ysis and inhibition, variants harboring Cys to Ala changes of the
residues were generated.
The consequences of thesemodiﬁcations onenzyme activitywere
varied. Three of the variants (C212A, C327A, and C386A) lacked
detectable activity (Table 1), while three other variants (C369A,
C401A, and C402A) had subtly reduced speciﬁc activities. The
remaining two variants (C242A and C445A) had speciﬁc activities
similar to the unaltered enzyme. EbSe and TCEP were then tested
against the active variants. Both compounds were potent inhibitors
of all of the active variants (including C369A), with no detectable dif-
ference in sensitivity compared to unmodiﬁed TbHK1 (Table 1).
In an effort to recover activity from the inactive Cys to Ala vari-
ants (C212A, C327A, and C386A), the three Cys residues were al-
tered by mutation to a more conserved residue, Ser. The C212S
variant had reduced yet detectable activity, while the other two
yielded activity barely above the threshold of the variability in
the assay. Notably, C212S remained sensitive to EbSe inhibition
(Table 1).
3.5. Effects of Cys variants on oligomerization
To explore the impact of Cys residue alteration on the protein ter-
tiary structure, native gels were used to resolve hexamer andmono-
mer abundance, which were then characterized by silver staining
and western blotting, respectively (Fig. 3A) (Chambers et al.,
2008b). Hexamer abundance was not altered in most of the variants
with C386A and C445A having 2-fold increases in oligomer abun-
dance (Fig. 3A). Two TbHK1 variants (C327A and C369A) had slightly
reduced levels ofmonomer (as determined by probingwith the anti-
six His antibody), while C445A had a 10-fold reduction in mono-
mer abundance, suggesting this residue inﬂuences oligomerization.
The proteins were also incubated with MPB and biotinylation of
monomeric TbHK1 scored in order to further assess the conse-
quences of Cys mutation on structure. Protein was resolved by na-
tive gel electrophoresis (4%), with monomer transferred to
nitrocellulose followed by western blotting with antisera to the
six His tag used for afﬁnity puriﬁcation to score relative protein
concentration or an anti-biotin antibody to determine the relative
level of biotinylation.EbSe IC50 (lM) TCEP IC50 (mM)
0.35 ± 0.07 6.6 ± 0.4
<WTc
<WT
0.55 ± 0.02 4.1 ± 0.3
0.26 ± 0.02 7.5 ± 0.4
0.29 ± 0.04 10 ± 0.7
0.43 ± 0.11 7.2 ± 0.2
0.52 ± 0.05 5.4 ± 0.1
Fig. 3. Relative hexamer, monomer, and free Cys abundance for TbHK1 and
variants. (A.) Relative hexamer and monomer abundance of TbHK1 and Cys
variants. Relative hexamer abundance (hatched bars) was determined by densi-
tometry of appropriately sized bands visualized by silver staining of a 4% native gel
followed by comparison to TbHK1 (lane 1). Relative monomer abundance (black
bars) was determined by western blot analysis of the appropriate region of a 4%
native gel using an anti-RGSH6 antibody and comparison to TbHK1. (B.) MPB
modiﬁcation of the monomer was determined by incubating variants with MPB (50
lM) for 30 min and monitoring the appropriate region of the gel by western
blotting using an anti-biotin antibody. Experiments were performed in triplicate
and standard deviation is indicated, with representative data included above each
bar graph.
Fig. 4. Negative stain TEM analysis of globular TbHK1 hexamers. Samples of WT
TbHK1 (upper) and C445A variant TbHK1 (lower) were analyzed using a JEOL JEM
1200 EX transmission electron microscope after negative staining. Inset contains
enlargement of four representative protein particles. Scale bar = 100 nm.
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TbHK1 variants, seven of the eight variants were labeled similarly
to WT protein (Fig. 3B). However, C445A had an increased numberof free Cys residues available for biotinylation by MPB per mono-
mer as compared to TbHK1. This amino acid alteration may lead
to an unstable monomer that, as a result of the modiﬁcation, has
many of its Cys residues exposed and available for MPB modiﬁca-
tion. Additionally, neither EbSe nor TCEP impact oligomerization of
TbHK1 (data not shown).3.6. Oligomers of C445A are indistinguishable from TbHK1 by electron
microscopy
To date, the oligomers of TbHK1 have been refractory to struc-
tural studies due to an inability to generate useful crystals. How-
ever, EM analysis of recombinant protein suggests that enzyme
oligomers are globular and roughly symmetrical, with an average
diameter of 18.25 ± 0.19 nm (Fig. 4). The C445A variant, which
has slightly greater abundance of hexamer in the native gel analy-
sis (Fig. 3A), had a similar distribution of sizes (average diame-
ter = 16.5 ± 2.8 nm), suggesting the mutation had relatively little
impact on gross architecture. Notably, the overall structure of the
hexamers suggests a ring-shaped tertiary structure.
Fig. 5. Potential scheme for EbSe-based oxidation of Cys residues in TbHK1.
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Currently there are a limited number of drugs available for the
treatment of African trypanosomiasis. These agents have draw-
backs – several are limited to treatment of infections before the
parasite has crossed the blood–brain barrier, while others are ac-
tive against one but not both human-infective subspecies of T. bru-
cei. Target-based drug discovery offers the advantage of assessing
drug/target interaction and allowing potential anticipation of pos-
sible resistance mechanisms.
TbHK1, which has been genetically and chemically validated as
a suitable target for therapeutic development, has been the subject
of several screening campaigns for small molecule inhibitors
(Chambers et al., 2008a; Dodson et al., 2010; Sharlow et al.,
2010b). The small molecule EbSe, the sulfur derivative EbS, and
several structural analogs of EbS were identiﬁed in these cam-
paigns, suggesting that the compounds could prove useful for
probing the enzymology of the protein. Further analysis revealed
that both EbSe and EbS were mixed inhibitors of TbHK1 (with re-
spect to ATP) and both were toxic to parasites (Sharlow et al.,
2010b). While the potency against recombinant enzyme and para-
sites was different (with IC50 values of 0.05 ± 0.03 and 2.0 ± 0.5 for
EbSe and EbS compared to EC50 values of 2.9 ± 0.28 and
0.030 ± 0.067 for the two compounds, respectively), both were able
to reduce parasite G6-P levels after acute exposure, suggesting that
at least one possible in vivo targets was TbHK1 (Sharlow et al.,
2010a,b). Recently, trypanothione reductase has been identiﬁed
as a second potential target (Lu et al., in press). With both targets
being essential to the parasite, it is difﬁcult to resolve which (if
either) are responsible for the toxic action of the molecules.
EbSe had previously been characterized as a mimic of glutathi-
one peroxidase, utilizing reduced glutathione to reduce hydrogen
peroxide and lipid hydroperoxides. Additionally, EbSe has also
been identiﬁed as a potent electrophile, facilitating inter- and
intramolecular disulﬁde linkages (Sakurai et al., 2006). For exam-
ple, EbSe was found to have reacted with up to 8 Cys residues of
human IDO, causing a change in conformation that led to IDO inac-
tivation (Terentis et al., 2010). Here, we have pursued a further dis-
section of the mode of action of TbHK1 inhibition by this group of
compounds with a particular focus on covalent Cys modiﬁcation.The results of these efforts suggest that the inhibitory activity of
EbSe against TbHK1 is likely the result of thiol oxidation of C327.
Initially, we found that TbHK1 inhibition by EbSe was not re-
lieved by enzyme/inhibitor dilution, which supported the idea that
the compound was indeed irreversibly modifying the enzyme. This
was in stark contrast to inhibition of a HK from Plasmodium falcipa-
rum (PfHK), which we have recently characterized (Harris et al.,
2013). While EbSe and EbS were 10-fold more potent inhibitors
of PfHK, inhibition by both was completely relieved by dilution
(Harris et al., 2013).
While the dilution experiments suggested that EbSe was irre-
versibly modifying TbHK1, the ﬁnding that EbSe inhibition was
not reversible on treatment with DTT supported the notion that
the inhibition was not due to the canonical promiscuous seleno-
sulﬁde formation that has been observed previously with EbSe.
This supposition was supported by the mass spectrometry analysis,
which revealed oxidized Cys species including sulfone and sulfonic
acid functionality at C103, C327, and C369, with the latter two sites
of oxidations detected only in the EbSe treated samples. Muta-
tional analysis revealed that C327 is essential while C369 could
be altered without notable consequence on either catalysis or EbSe
sensitivity, suggesting that inhibition of TbHK1 is a consequence of
oxidation of the former Cys. Lacking a solved structure for either
monomeric or heteromeric TbHK1, it is difﬁcult to resolve the rea-
sons for the observed inhibition as both C327 and C369 are pre-
dicted (based on modeling) to be on the large lobe of the enzyme
at some distance from the active site.
EbSe has been described as a thiol oxidant in other studies
(Schewe, 1995; Sakurai et al., 2006) suggesting a model for TbHK1
thiol oxidation (Fig. 5). In the model, the Se atom of EbSe is at-
tacked by the Cys SH followed by a proton transfer. The resultant
S-Se conjugate is then hydrolyzed, with a subsequent proton trans-
fer followed by deprotonation of the OH to yield the initial Cys sulf-
oxide. This functionality was not observed by MS/MS analysis, and
is expected to undergo rapid in situ oxidation to the corresponding
sulfone and sulfonic acids that were observed by MS. In principle,
the initial conjugation with EbSe would be reversible prior to
hydrolysis, accounting for the ﬁnding that promiscuous Cys
oxidation was not observed. This mechanism would also poten-
tially explain the reduced potency of EbS. EbS is structurally
160 A.C. Joice et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 154–160nearly-identical to EbSe but the Se-bearing molecule would likely
be a more potent oxidizing agent.
Despite its potentially promiscuous nature, EbSe is non-toxic to
humans and is currently deployed in phase III clinical trials for
treatment of ischemic stroke (Stroke Trials Registry Home Page,
as of 08/16/2013) and was found to improve the outcome of pa-
tients suffering stroke (Yamaguchi et al., 1998). These studies
and others that indicate that EbSe has antibacterial properties as
a consequence of inhibition of bacterial thioredoxin reductases
(Lu et al., 2013) suggest that the benzisoselenazol derivatives could
prove useful for therapeutic development.
Acknowledgements
This work was supported in part by the US National Institutes of
Health 1R15AI075326 to JCM. We thank Jennifer Bethard (Depart-
ment of Cell and Molecular Pharmacology, Mass Spectrometry
Facility, Medical University of South Carolina) for the mass spec-
trometry analysis.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijpddr.2013.08.
002.
References
Bayer, E.A., Zalis, M.G., Wilchek, M., 1985. 3-(N-Maleimido-propionyl)biocytin: a
versatile thiol-speciﬁc biotinylating reagent. Anal. Biochem. 149, 529–536.
Borges, V.C., Rocha, J.B., Nogueira, C.W., 2005. Effect of diphenyl diselenide, diphenyl
ditelluride and ebselen on cerebral Na(+), K(+)-ATPase activity in rats.
Toxicology 215, 191–197.
Brun, R., Blum, J., Chappuis, F., Burri, C., 2010. Human African trypanosomiasis.
Lancet 375, 148–159.
Chambers, J.W., Fowler, M.L., Morris, M.T., Morris, J.C., 2008a. The anti-
trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1.
Mol. Biochem. Parasitol. 158, 202–207.
Chambers, J.W., Kearns, M.T., Morris, M.T., Morris, J.C., 2008b. Assembly of
heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a
regulable enzyme. J. Biol. Chem. 283, 14963–14970.Chambers, J.W., Morris, M.T., Smith, K.S., Morris, J.C., 2008c. Residues in an ATP
binding domain inﬂuence sugar binding in a trypanosome hexokinase.
Biochem. Biophys. Res. Commun. 365, 420–425.
Dodson, H.C., Lyda, T.A., Chambers, J.W., Morris, M.T., Christensen, K.A., Morris, J.C.,
2010. Quercetin, a ﬂuorescent bioﬂavanoid, inhibits Trypanosoma brucei
hexokinase 1. Exp. Parasitol. 127, 423–428.
Harris, M.T., Walker, D.M., Drew, M.E., Mitchell, W.G., Dao, K., Schroeder, C.E.,
Flaherty, D.P., Weiner, W.S., Golden, J.E., Morris, J.C., 2013. Interrogating a
hexokinase-selected small molecule library for inhibitors of Plasmodium
falciparum hexokinase. Antimicrob. Agents Chemother. 57, 3717–3731.
Lu, J., Vlamis-Gardikas, A., Kandasamy, K., Zhao, R., Gustafsson, T.N., Engstrand, L.,
Hoffner, S., Engman, L., Holmgren, A., 2013. Inhibition of bacterial thioredoxin
reductase: an antibiotic mechanism targeting bacteria lacking glutathione.
FASEB J. 27, 1394–1403.
Lu, J., Vodnala, S.K., Gustavsson, A.L., Gustafsson, T.N., Sjoberg, B., Johansson, H.A.,
Kumar, S., Tjernberg, A., Engman, L., Rottenberg, M.E., Holmgren, A., in press.
Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione
reductase of Trypanosoma brucei. J. Biol. Chem. http://dx.doi.org/
jbc.M113.495101
Misset, O., Opperdoes, F.R., 1984. Simultaneous puriﬁcation of hexokinase, class-I
fructose-bisphosphate aldolase, triosephosphate isomerase and
phosphoglycerate kinase from Trypanosoma brucei. Eur. J. Biochem. 144, 475–
483.
Misset, O., Bos, O.J., Opperdoes, F.R., 1986. Glycolytic enzymes of Trypanosoma
brucei. Simultaneous puriﬁcation, intraglycosomal concentrations and physical
properties. Eur. J. Biochem. 157, 441–453.
Morris, M.T., DeBruin, C., Yang, Z., Chambers, J.W., Smith, K.S., Morris, J.C., 2006.
Activity of a second Trypanosoma brucei hexokinase is controlled by an 18-
amino-acid C-terminal tail. Eukaryot. Cell 5, 2014–2023.
Sakurai, T., Kanayama, M., Shibata, T., Itoh, K., Kobayashi, A., Yamamoto, M., Uchida,
K., 2006. Ebselen, a seleno-organic antioxidant, as an electrophile. Chem. Res.
Toxicol. 19, 1196–1204.
Schewe, T., 1995. Molecular actions of ebselen – an antiinﬂammatory antioxidant.
Gen. Pharmacol. 26, 1153–1169.
Sharlow, E., Golden, J.E., Dodson, H., Morris, M., Hesser, M., Lyda, T., Leimgruber, S.,
Schroeder, C.E., Flaherty, D.P., Weiner, W.S., Simpson, D., Lazo, J.S., Aube, J.,
Morris, J.C., 2010a. Identiﬁcation of Inhibitors of Trypanosoma brucei
Hexokinases, Probe Reports from the NIH Molecular Libraries Program,
Bethesda (MD).
Sharlow, E.R., Lyda, T.A., Dodson, H.C., Mustata, G., Morris, M.T., Leimgruber, S.S.,
Lee, K.H., Kashiwada, Y., Close, D., Lazo, J.S., Morris, J.C., 2010b. A target-based
high throughput screen yields Trypanosoma brucei hexokinase small molecule
inhibitors with antiparasitic activity. PLoS Negl. Trop. Dis. 4, e659.
Terentis, A.C., Freewan, M., Sempertegui Plaza, T.S., Raftery, M.J., Stocker, R.,
Thomas, S.R., 2010. The selenazal drug ebselen potently inhibits indoleamine
2,3-dioxygenase by targeting enzyme cysteine residues. Biochemistry 49, 591–
600.
Yamaguchi, T., Sano, K., Takakura, K., Saito, I., Shinohara, Y., Asano, T., Yasuhara, H.,
1998. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind
clinical trial. Ebselen Study Group. Stroke 29, 12–17.
